Loading
A phase 1/2 trial of Gemcitabine, FOLFIRI, Irinotecan in metastatic cancer and ovarian cancer, run by Artios Pharma Ltd, now recruiting.
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04657068 by Artios Pharma Ltd, with 542 participants planned, started 2021-01-27 and due to reach its primary completion in 2028-01. Interventions recorded: ART0380, Gemcitabine, Irinotecan. Conditions listed: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Artios Pharma, Metastatic cancer (cancer that has spread).
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Metastatic cancer (cancer that has spread).
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), Colorectal cancer.
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan).
Shares Irinotecan (and liposomal irinotecan), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/